Try our Advanced Search for more refined results

FTC Says Endo, Impax Cut 2nd Opana ER Pay-For-Delay Deal

By Bryan Koenig (January 25, 2021, 4:36 PM EST) -- The Federal Trade Commission filed a new antitrust complaint Monday accusing Endo Pharmaceuticals and Impax Laboratories of striking a second deal to stave off competition to the Opana ER opioid pain medication even as an earlier FTC enforcement action over the same drug was moving forward....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!